Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosiglitazone in Non-Diabetic Stage 4 CKD
NCT00452166Phase 3Terminated
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2007
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rosiglitazone in insulin resistance (IR), sponsored by Leiden University Medical Center. Primary endpoint: Insulin Sensitivity Index at 12 weeks. Started Apr 2007; status: terminated.
02
Drugs
rosiglitazone
03
Conditions
insulin resistance (IR)
Beyond the preview
Go deeper on NCT00452166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00452166.